Ruibo Biologics and Boehringer Ingelheim Achieve New Milestone in siRNA Collaboration for MASH

May 6, 2026 – Suzhou Ribo Life Science Co., Ltd. (Stock Code: 6938, Hong Kong Stock Exchange) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure, collectively referred to as “Ribo Life Science”) jointly announced another significant breakthrough in their liver disease innovative therapy project conducted in collaboration with Boehringer Ingelheim (“Boehringer”). This marks the third key milestone successfully achieved under their partnership, which focuses on innovative therapies for liver diseases, including Metabolic Dysfunction-Associated Steatohepatitis (MASH). The achievement highlights the continued progress in their collaborative research and development efforts, as well as a solid step forward in the translational application of siRNA technology within the field of metabolic liver diseases.

MASH is a severe progressive fatty liver disease that can gradually progress to liver fibrosis, cirrhosis, liver failure, and even liver cancer. Currently, more than 200 million people worldwide are affected by MASH. With the continuous increase in disease burden, there is an urgent clinical need for innovative therapies that can slow disease progression and protect liver health. The core goal of the in-depth collaboration between Ribo Life Science and Boehringer Ingelheim is to bring a wider range of potential treatment options to patients with MASH and fill the gap in clinical treatment.

siRNA Therapy Aims to Silence Pathogenic Genes by Targeting Messenger RNA (mRNA). Ribo Life Science's Liver-Targeted Delivery Technology Achieves Selective Uptake by Hepatocytes, Enabling Action on Targets That Are Difficult to Reach with Traditional Small Molecules or Antibodies.

This milestone fully reflects the efficient results of the collaboration between Ribo Life Science and Boehringer Ingelheim, as well as their shared goal of addressing unmet clinical needs in the field of liver and cardiometabolic diseases. This achievement further solidifies Ribo Life Science's position as a strategic partner for global pharmaceutical companies, highlighting the commercial value of its siRNA technology platform. Ribo Life Science will continue to deepen the partnership, striving to achieve more successes by 2026 and beyond.

Boehringer Ingelheim is a globally leading biopharmaceutical company, operating in two major business areas: human pharmaceuticals and animal health. The company’s R&D investment ranks among the top in the industry, focusing on researching breakthrough therapies to address significant unmet medical needs, thereby helping to improve or extend lives. Since its founding in 1885, Boehringer Ingelheim has remained an independent, family-owned enterprise, always prioritizing long-term development and integrating sustainable practices throughout the entire value chain. With approximately 54,300 employees worldwide, the company serves over 130 markets, committed to building a healthier and more sustainable future. For more information, please visit: www.boehringer-ingelheim.com.

Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science, Hong Kong Stock Exchange code: 6938) is an innovative clinical-stage company dedicated to developing small nucleic acid (RNAi)-based therapeutics. With its strong R&D capabilities and integrated technology platform, Ribo Life Science has built a robust product pipeline aimed at addressing unmet clinical needs for serious diseases. For more information, please visit www.ribolia.com.

Ribocure Pharmaceuticals AB, a subsidiary of Ribo Life Science, is dedicated to the global research and development of life-saving oligonucleotide therapies. Drawing on extensive experience in translational medicine and clinical development, Ribocure focuses on addressing significant unmet medical needs for patients with major diseases and rare conditions affecting the liver, cardiovascular system, kidneys, and cancer worldwide. For more information, please visit www.ribocure.com.